Dimethyl fumarate dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Dimethyl fumarate is an approved multiple sclerosis drug, and the cleanest drug we have for switching on NRF2. In mice, it did not extend lifespan. But the mice only got about 35 percent of the planned dose, and the authors say that may explain it.
Evidence grade for Dimethyl fumarate: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 3 completed trials, 54 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 54
- Human studies
- 3
- Found nothing
- 1
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved as Tecfidera for relapsing multiple sclerosis, the kind that flares up and then settles. Not approved for any ageing use.
4 effects reported, 3 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Immune system and inflammation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Dimethyl fumarate is a prescription pill for multiple sclerosis. It switches on NRF2, the body's antioxidant switch. That is the same idea behind many longevity supplements.
What people take it for
- Switching on NRF2 to slow ageing.
- A stronger version of what supplements like sulforaphane promise.
What studies in people showed
In multiple sclerosis, it cut relapses. In the main trial, 27 percent had a relapse on it, against 46 percent on a dummy pill. In 54 people with a slower type of multiple sclerosis, it did nothing. Nobody has tested it for ageing. Now mice. It did not make either sex live longer. But the mice got only about 35 percent of the planned dose.
What people report
Reports, not study results
The good
- In multiple sclerosis, fewer relapses.
The bad
- Flushing and gut problems, mostly early.
- Low white blood cells (lymphocytes). Long, severe drops are linked to a rare, serious brain infection.
- More infections in the slow multiple sclerosis study.
Where these come from: The side effects are from the multiple sclerosis trials on this page. We have no user reports.
My bottom line
The mouse test was not fair, so the NRF2 idea is still open. That does not make this a supplement. It needs blood tests, and I would not take it for ageing.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Dimethyl fumarate has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Immune functionno headcount stated · 2 studies
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. This is an approved medicine. So the missing study in people is for this use, not for the drug. Drug makers paid to test it for what it is approved for. The record on this one is set out below.
- Living longer1 animal or lab study
34 of the 36 indexed goals have no study of any kind behind Dimethyl fumarate
No study in people, animals or cells on this page reports a result for these. That does not prove Dimethyl fumarate does nothing for them. It does mean anything you have heard about Dimethyl fumarate and one of these did not come from a study cited here.
Show full evidence
What is Dimethyl fumarate?
Dimethyl fumarate is an approved multiple sclerosis drug, and the cleanest drug we have for switching on NRF2. In mice, it did not extend lifespan. But the mice only got about 35 percent of the planned dose, and the authors say that may explain it.
NRF2 is the master switch for the body's antioxidant and clean-up response. Switching it on is one of the most quoted reasons behind longevity supplements. Sulforaphane, curcumin and a long list of plant compounds are all sold on this idea. Dimethyl fumarate is the only NRF2 switch-on drug that is approved with a known dose. That makes it the best way to test whether switching on NRF2 makes you live longer.
In the mouse lifespan program's 2024 run, it did not make either sex live longer. But this failure comes with a real asterisk, from the authors themselves. The amount of dimethyl fumarate in the food averaged 35 percent of the planned dose. They say this may explain why lifespan did not change.
A no at about a third of the planned dose is weaker than a no at the full dose. Reporting it without that warning would mislead.
How does Dimethyl fumarate work?
Dimethyl fumarate is a reactive chemical that grabs onto KEAP1, the protein that normally marks NRF2 for disposal. With KEAP1 knocked out, NRF2 builds up and moves into the cell's control center. There it switches on antioxidant genes, including ones that make glutathione and the clean-up enzymes NQO1 and HO-1. It also drains glutathione at first. It has immune effects that have nothing to do with NRF2, including lowering lymphocytes, a type of white blood cell. That matters for how it helps in multiple sclerosis, and it is also its main risk.
What have studies in people found about Dimethyl fumarate?
A solid record as an approved drug for multiple sclerosis and psoriasis. Nothing on ageing in people.
- Approved for relapsing multiple sclerosis. In the main two year trial (DEFINE), 27 and 26 percent on the two doses had a relapse, against 46 percent on a dummy pill. Disability got worse in 16 and 18 percent, against 27 percent.
- In a second two year trial (CONFIRM), it also cut relapses. Its effect on disability could have been chance.
- In 54 people with primary progressive multiple sclerosis, a year on it changed nothing that was measured, including a nerve damage marker.
- Used in Europe for psoriasis, where drugs of this type have a long history.
- Flushing and gut problems are common early and usually settle.
- Low lymphocytes are the big risk. Long, severe drops have been linked to a rare, serious brain infection (PML), so lymphocyte counts are checked.
- No human study has looked at lifespan, healthy years or anything else about ageing.
What this does not tell you: The human evidence is about an autoimmune disease of the brain and spinal cord. It does not carry over to healthy ageing. The mouse lifespan failure is weakened because the mice got only about 35 percent of the planned dose. So the question of NRF2 and lifespan is closer to untested than answered.
The state of the research
This page is why a failed test needs reading, not just counting. Taken at face value, the most careful lifespan program in the field tested the best-known NRF2 switch-on drug and found nothing. That would be a serious problem for a lot of supplements sold on NRF2. Read properly, the mice got about 35 percent of the planned dose, and the authors offer that as the likely reason.
So the honest position is that the NRF2 idea has not yet had a fair lifespan test. Anyone citing this run as evidence against switching on NRF2 is reading too much into it. So is anyone who ignores the result.
The National Institute on Aging runs the Interventions Testing Program at three separate labs: The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a mixed breed made by crossing four strains, so a result cannot be a quirk of one strain. Compounds go in the food. Both sexes are tested. Each group is big enough to spot about a 10 percent change in lifespan. Results are checked with one test for typical lifespan and another for the longest-lived mice. The failures are published next to the wins. No other ageing research has all of that together. That is why a no from this program means much more than a no from one lab.
The evidence, in charts
Fig. 1a · how many people
54people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Neurology: Neuroimmunology & Neuroinflammation 2021 | 54 | 100% |
The whole total is one study of 54. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 sources here are studies in people. The rest is not.
- Study in people · done in people375%
- Animal study · done in animals125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2012 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 144.1 Da. A small molecule, not a peptide.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Very short as the parent compound, which is rapidly hydrolysed to monomethyl fumarate, the active metabolite, with a half-life of roughly one hour.
No amino acid sequence is on file for Dimethyl fumarate, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2012Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
In relapsing multiple sclerosis, dimethyl fumarate roughly halved the relapse rate over two years compared with a dummy pill, and slowed disability. 27% and 26% on the two doses had a relapse, against 46% on the dummy pill. This is the trial behind the approval. Flushing, gut problems and lower lymphocyte counts were the price.
Patients with relapsing-remitting MS randomised double-blind to BG-12 (dimethyl fumarate) 240 mg twice daily, three times daily, or placebo for 2 years (DEFINE). Proportion with a relapse 27% and 26% versus 46% on placebo (p<0.001); annualised relapse rate 0.17 and 0.19 versus 0.36, relative reductions 53% and 48%; confirmed disability progression 16% and 18% versus 27%, relative reductions 38% (p=0.005) and 34% (p=0.01). Fewer gadolinium-enhancing and new T2 lesions. Flushing, gastrointestinal events, lower lymphocyte counts and raised aminotransferases on BG-12.
- Study in people2012Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
The second approval trial, with an injected drug, glatiramer, as well as a dummy pill for comparison. Dimethyl fumarate cut relapses compared with the dummy pill, and so did glatiramer. Neither clearly slowed disability. It was not built to say which drug is better.
Patients with relapsing-remitting MS randomised to BG-12 240 mg twice or three times daily, glatiramer acetate, or placebo for 2 years (CONFIRM). Annualised relapse rate 0.22 and 0.20 on BG-12 and 0.29 on glatiramer versus 0.40 on placebo (relative reductions 44%, 51% and 29%). Reductions in disability progression of 21%, 24% and 7% versus placebo fell short of significance. Fewer new or enlarging T2 and new T1 lesions on all three (p<0.001). Flushing and gastrointestinal events on BG-12; lymphocyte counts fell; no malignancies or opportunistic infections reported.
- Study in people2021Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.
In primary progressive multiple sclerosis, a year of dimethyl fumarate changed nothing that was measured, including the nerve damage marker it was meant to lower. Fifty-four people, one year, a clean no. Infections, low lymphocytes, flushing and gut problems were more common on the drug.
54 patients with primary progressive MS randomised double-blind to dimethyl fumarate 240 mg or placebo for 48 weeks. Change in CSF neurofilament light chain did not differ (mean difference 99 ng/L, 95% CI -292 to 491). No secondary or tertiary efficacy outcome was affected. Infections, lymphopenia, flushing and gastrointestinal effects more frequent on dimethyl fumarate; serious adverse events similar.
- Animal study2024Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not
In mice. In the NIA mouse lifespan program, dimethyl fumarate did not clearly make either sex live longer at the dose and method used. The amount in the food averaged 35 percent of the planned dose, which the authors say may explain the lack of effect. Note the conflicts of interest: two authors run a company that supplied the astaxanthin used, and others hold patents or company stakes in drugs that clear worn-out cells.
Interventions Testing Program. Dimethyl fumarate did not increase lifespan significantly in either sex at the dose and method of administration tested. The authors report that the amount in the diet averaged 35 percent of the target dose, which they state may explain the absence of lifespan effects. Note the disclosed conflicts in this paper: two authors run a company supplying the astaxanthin used, and others hold senolytic patents or company interests.
Common questions
Has Dimethyl fumarate been tested in people?
Yes. 54 people given it across 3 completed trials cited here, 1 of which found nothing. Dimethyl fumarate is an approved multiple sclerosis drug, and the cleanest drug we have for switching on NRF2. In mice, it did not extend lifespan. But the mice only got about 35 percent of the planned dose, and the authors say that may explain it.
What is the Dimethyl fumarate dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved as Tecfidera for relapsing multiple sclerosis, the kind that flares up and then settles. Not approved for any ageing use.
Is Dimethyl fumarate FDA-approved?
FDA-approved as Tecfidera for relapsing multiple sclerosis, the kind that flares up and then settles. Not approved for any ageing use.
Does activating NRF2 extend lifespan?
Untested more than answered. The one try with a well-known NRF2 switch-on drug found no lifespan effect. But the mice got about 35 percent of the planned dose, and the authors say that may explain it. That leaves the question open.
Should I take dimethyl fumarate for longevity?
No. It needs lymphocyte blood tests, because long, severe drops in lymphocytes have been linked to a serious brain infection. There is no sign of an ageing benefit to weigh against that. If NRF2 is what interests you, the honest answer is that nobody has shown switching it on makes a mammal live longer.
Is this the same as taking sulforaphane or curcumin?
They share an idea about how they work, and differ in almost everything else that matters: strength, dose certainty, how well they are absorbed, and how much evidence there is. Dimethyl fumarate is a prescription drug with a known dose. That is exactly why it was picked for the lifespan test.